Peripherally administered GM-CSF interferes with scopolamine-induced amnesia in mice: Involvement of interleukin-1

Brain Research

Volumn 729, Issue 2, 1996, Pages 285-288

  Bianchi, Mauro ^a   Sacerdote, Paola ^a   Panerai, Alberto E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Interleukin 1; Passive avoidance; Recombinant granulocyte macrophage colony stimulating factor; Scopolamine induced amnesia

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

EID: 0030581283     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00591-4     Document Type: Article

References (12)

1. a interferes with scopolamine-induced amnesia in mice, Cogn. Brain Res., 1 (1993) 257-259.
2. B receptor antagonist CGP 35348 in the mouse, Cogn. Brain Res., 1 (1993) 135-136.
3. [3] Bianchi, M. and Panerai, A.E., Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse, NeuroReport, 4 (1993) 1046-1048.
4. [4] Bianchi, M., Ferrario, P., Zonta, N. and Panerai, A.E., Effects of interleukin-1β and interleukin-2 on amino acids levels in mouse cortex and hippocampus, NeuroReport, 6 (1995) 1689-1692.
5. [5] Black, P.H., Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain, Antimicrob. Agents Chemother., 38 (1994) 7-12.
6. [6] Chang, Y., Albright, S. and Lee, F., Cytokines in the central nervous system: expression of macrophage colony stimulating factor and its receptor during development. J. Neuroimmunol., 52 (1994) 9-17.
7. [7] Dunn, A.J., Antoon, M. and Chapman, Y., Reduction of exploratory behavior effects of peripherally injected interleukin-1 involves brain corticotropin-releasing factor, Brain Res. Bull, 26 (1991) 539-542.
8. [8] Grant, S.M. and Heel, R.C., Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelo-suppression, Drugs, 43 (1992) 516-560.
9. [9] Lee, J.H. and El-Kakahany, E.E., Heterogeneity of binding of muscarinic receptor antagonists in rat homogenates, J. Pharmacol. Exp. Ther., 233 (1985) 707-714.
10. [10] Lieschke, G.J. and Burgess, A.W., Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, N. Engl. J. Med., 327 (1992) 28-34.
11. [11] Lindemann, A., Riedel, D., Oster, W., Meuerr, S.C., Blohm, D., Mertelsmann, R.H. and Herrmann, F., Granulocyte macrophage colony-stimulating factor induces interleukin-1 production by human polymorphonuclear neutrophils, J. Immunol., 140 (1988) 837-839.
12. [12] Vial, T. and Descotes, J., Clinical toxicity of cytokines used as haemopoietic growth factors, Drug Safety, 13 (1995) 371-406.